Proceedings from the 4 NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022.
作者信息
Sinha Rashmi, De Benedetti Fabrizio, Grom Alexei A
机构信息
Systemic JIA Foundation, Cincinnati, OH, USA.
Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
出版信息
Pediatr Rheumatol Online J. 2024 Jan 5;21(Suppl 1):91. doi: 10.1186/s12969-023-00863-2.
Abstract
摘要
相似文献
1
Proceedings from the 4 NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022.
Pediatr Rheumatol Online J. 2024 Jan 5;21(Suppl 1):91. doi: 10.1186/s12969-023-00863-2.
2
The 4 NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study.
Pediatr Rheumatol Online J. 2024 Jan 3;21(Suppl 1):150. doi: 10.1186/s12969-023-00866-z.
3
Proceedings from the 2 Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019.
Pediatr Rheumatol Online J. 2020 Jul 15;18(Suppl 1):53. doi: 10.1186/s12969-020-00444-7.
4
The 4 NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?
Pediatr Rheumatol Online J. 2024 Jan 5;21(Suppl 1):79. doi: 10.1186/s12969-023-00867-y.
5
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA.
Pediatr Rheumatol Online J. 2024 Jan 5;21(Suppl 1):87. doi: 10.1186/s12969-023-00865-0.
6
The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease.
Pediatr Rheumatol Online J. 2024 Jan 5;21(Suppl 1):114. doi: 10.1186/s12969-023-00864-1.
7
Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis.
ACR Open Rheumatol. 2019 Jul 13;1(6):345-349. doi: 10.1002/acr2.11048. eCollection 2019 Aug.
8
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe.
Pediatr Rheumatol Online J. 2024 Jan 5;21(Suppl 1):86. doi: 10.1186/s12969-023-00868-x.
9
Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
Arthritis Rheumatol. 2022 Jul;74(7):1271-1283. doi: 10.1002/art.42099. Epub 2022 May 31.
10
Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.
Rheumatol Int. 2022 May;42(5):879-889. doi: 10.1007/s00296-021-04980-7. Epub 2021 Sep 7.
本文引用的文献
1
Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
Ann Rheum Dis. 2022 Mar;81(3):406-415. doi: 10.1136/annrheumdis-2021-220578. Epub 2021 Nov 17.
2
Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease.
Rheum Dis Clin North Am. 2021 Nov;47(4):585-606. doi: 10.1016/j.rdc.2021.06.003. Epub 2021 Aug 21.
3
Targeting interferon-γ in hyperinflammation: opportunities and challenges.
Nat Rev Rheumatol. 2021 Nov;17(11):678-691. doi: 10.1038/s41584-021-00694-z. Epub 2021 Oct 5.
4
Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
Ann Rheum Dis. 2021 May;80(5):617-625. doi: 10.1136/annrheumdis-2020-217470. Epub 2020 Dec 4.
5
Proceedings from the 2 Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019.
Pediatr Rheumatol Online J. 2020 Jul 15;18(Suppl 1):53. doi: 10.1186/s12969-020-00444-7.
6
Emergent high fatality lung disease in systemic juvenile arthritis.
Ann Rheum Dis. 2019 Dec;78(12):1722-1731. doi: 10.1136/annrheumdis-2019-216040. Epub 2019 Sep 27.
7
Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
Arthritis Rheumatol. 2019 Nov;71(11):1943-1954. doi: 10.1002/art.41073. Epub 2019 Oct 1.
8
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Ann Rheum Dis. 2017 Jan;76(1):166-172. doi: 10.1136/annrheumdis-2015-209020. Epub 2016 Jun 13.
9
Macrophage activation syndrome in the era of biologic therapy.
Nat Rev Rheumatol. 2016 May;12(5):259-68. doi: 10.1038/nrrheum.2015.179. Epub 2016 Mar 24.
10
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
Arthritis Rheumatol. 2016 Jan;68(1):218-28. doi: 10.1002/art.39407.
Zotero 插件